Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
One of the pathophysiological features of type 2 diabetes is the progressive decrease in pancreatic beta-cell mass. Therefore, prevention of the progressive decrease in beta-cell mass and maintenance of beta-cell mass are considered as therapeutics in type 2 diabetes. We aimed to elucidate the beta-cell mass regulation mechanism by glucokinase. As a result, administration of a glucokinase activator to a mouse model of obese diabetes did not increase insulin secretion and beta-cell mass. On the other hand, glucokinase inactivation improved glucose tolerance by maintaining beta-cell function and mass.
|